The History of Women's HRT: From Premarin to Bioidentical

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

Ask a room of women in their fifties what they know about hormone therapy and you'll hear a strange mix of fear, half-remembered headlines, and a mother's advice from 1994. Somebody always says "isn't that the stuff that gives you cancer?" Somebody else swears her gynecologist handed her a patch and her life came back. Both of them are reacting to a story that's more than eighty years old, and most people only know the last chapter.

I'm Dr. Farhan Abdullah, an internal medicine physician, and at Magnolia Functional Wellness in Southlake I talk about this history almost every week. Not because I'm nostalgic. Because you can't make sense of today's guidance on estrogen and progesterone without knowing how medicine got here, and how badly the pendulum swung in both directions. So let's walk through it.

Where Premarin came from, and why it dominated for decades

The modern era starts with a drug most women have heard of by name. Premarin, a mix of conjugated equine estrogens derived from the urine of pregnant mares, reached the American market in the early 1940s. It was an odd origin story, honestly. Chemists were looking for a reliable, orally active estrogen at a time when most options had to be injected, and pregnant horses turned out to be an abundant source.

For a long time it was simply what doctors prescribed. Menopause was framed as a deficiency state, something to be corrected, and in 1966 a gynecologist named Robert Wilson published a bestseller called Feminine Forever that pushed the idea hard. Estrogen for every woman, indefinitely, to stay youthful. That book was enthusiastic, commercially backed, and much too confident for the evidence of its day.

Then came the first correction. In the mid-1970s, studies reported a sharp rise in endometrial cancer among women taking estrogen on its own. The reason is biological and fairly simple: estrogen stimulates the lining of the uterus, and without a counterbalance that stimulation can go wrong. The fix was to add a progestogen for women who still had a uterus, which is why combined therapy became standard. If you've ever wondered why your prescriber insists on progesterone alongside estrogen, that's the origin. It wasn't an upsell. It was a safety lesson learned the hard way.

The observational era: lots of optimism, not enough proof

Through the 1980s and 1990s, large observational studies suggested that women who took hormones had less heart disease and fewer fractures. By the mid-1990s, hormone therapy was among the most commonly prescribed medications in the country. The logic seemed sound. Estrogen improves cholesterol numbers, supports blood vessels, protects bone. Why wouldn't it protect the heart?

Here's the catch, and it's one I think about with every claim I read in medicine. Women who chose to take hormones back then tended to be healthier, wealthier, and more engaged with their care than women who didn't. Observational data can't fully separate the effect of a pill from the effect of the person swallowing it. The field needed a randomized trial. It got one, and the result rattled everyone.

2002: the Women's Health Initiative changes everything overnight

The Women's Health Initiative, usually shortened to WHI, enrolled thousands of postmenopausal women to test hormone therapy against placebo for the prevention of chronic disease. In July 2002, the estrogen plus progestin arm was stopped early. In the principal results published in JAMA by Rossouw and colleagues, 16,608 women aged 50 to 79 with an intact uterus had been randomized to conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily, or placebo. After a mean of 5.2 years, the monitoring board halted the trial because invasive breast cancer had crossed the stopping boundary and overall risks appeared to exceed benefits. The reported hazard ratios were 1.29 for coronary heart disease, 1.26 for breast cancer, and 1.41 for stroke.

The news landed like a bomb. Prescriptions collapsed. Women who'd felt well for years stopped abruptly and often felt terrible. A generation of physicians stopped feeling comfortable raising the subject at all, and a generation of women got told, sometimes flatly, that hormones were dangerous and they should just tough out the hot flashes.

I want to be fair to everyone in that story, including the researchers. The trial did exactly what a good trial should do: it tested a belief and found the belief wanting, for that specific drug combination, in that specific population. The problem wasn't the science. The problem was how the result got flattened into a single headline.

The details everybody skipped

Look at who was in that trial. The women were, on average, well past menopause when they started. Many were in their sixties and seventies. That's not who typically walks into my office with night sweats, shredded sleep, and a brain that feels like it's wrapped in cotton at age 49.

And it wasn't one trial. The estrogen-alone arm, in women who'd had a hysterectomy, told a different story. In the 2004 JAMA report from Anderson and colleagues, 10,739 women received conjugated equine estrogen 0.625 mg daily or placebo. The intervention was stopped early in 2004, after an average of 6.8 years, but the hazard ratio for breast cancer came in at 0.77 (confidence interval 0.59 to 1.01), and for coronary heart disease 0.91. Stroke risk was higher, at 1.39. So the picture split: estrogen with a synthetic progestin looked different from estrogen alone, and neither looked like a miracle or a poison.

Age and timing matter enormously here, and the trial wasn't designed to answer that question cleanly. Which brings us to the follow-up everyone should know about.

The timing hypothesis gets tested

If the WHI population skewed older, did the age at which a woman starts hormones change what happens to her arteries? Researchers built a trial specifically to ask. The ELITE study, reported in the New England Journal of Medicine by Hodis and colleagues in 2016, randomized 643 healthy postmenopausal women to oral estradiol 1 mg daily (with sequential vaginal progesterone gel for women who had a uterus) or placebo. Women were stratified by time since menopause: under six years, or ten years and beyond.

After a median of five years, carotid artery wall thickening progressed more slowly with estradiol in the early group, 0.0044 mm per year versus 0.0078 mm per year on placebo. In the women ten or more years past menopause, the rates were similar between groups. That doesn't prove hormones protect hearts, and I'd be wary of anyone who says it does. It's a surrogate marker, not a heart attack count. But it supports the idea that the same therapy can behave differently depending on when it's started, and that "hormones are dangerous" and "hormones are safe" were both too blunt.

That's the lens I use in practice. I'm not telling you what I think about hormone therapy in general. I'm asking who you are, how long it's been since your last period, what your family history looks like, what your labs show, and what's actually bothering you.

"Bioidentical" and where it fits

After 2002, a lot of women went looking for something that felt safer, and "bioidentical" became the word everyone reached for. Let me be plain about what it means and what it doesn't. It describes a molecule with the same chemical structure as a hormone your body makes, estradiol and progesterone being the classic examples. It does not describe a regulatory category, a safety guarantee, or a better outcome. It's a marketing term as much as a scientific one, and I'd treat it with the same skepticism I'd give "natural."

What matters more than the label is the specific product, the dose, the route, whether you have a uterus, and what the evidence says about your particular combination. Oral, patch, gel, and vaginal routes behave differently in the body. Some women do better with transdermal estradiol, particularly if they have certain clotting or metabolic risks. Others do fine on oral. This is a conversation, not a slogan. If you want to read more about how I think through the choices, the guide on women's hormone imbalance in DFW and why standard labs come back normal is a good starting point.

What this history means if you're sitting in my exam room

Three lessons stick with me from the whole saga.

First, evidence beats enthusiasm, whether the enthusiasm is a 1960s bestseller or a 2020s influencer. Second, a trial answers the question it asked, and sometimes the headline outruns the data. Third, individualization isn't a buzzword. It's the entire point. A healthy 50-year-old with severe vasomotor symptoms and a 70-year-old with long-standing cardiovascular disease are not the same patient, and a good plan reflects that.

If you're weighing this decision, a few questions are worth bringing to any appointment. How long has it been since my last period? What does my personal and family history say about breast cancer, blood clots, and heart disease? Which symptoms are actually driving this, and would they respond to something other than hormones? How will we know it's working, and when do we reassess? A good clinician welcomes those questions. If you get defensiveness or a canned speech in return, that tells you something too. I'd also add that symptoms tend to shift over the years, so a plan that fits at 49 deserves a fresh look at 55.

In practice, at Magnolia Functional Wellness, a first visit usually involves a detailed symptom history, a review of your personal and family medical background (breast cancer, clotting, heart disease, and so on), and a look at labs that fit your situation. Then we talk about options, including the option of not starting. Some women decide hormone therapy isn't right for them, and that's a perfectly legitimate outcome. Others are relieved to finally hear a balanced answer. If you'd like to see how we approach it, our women's hormone replacement therapy page lays out what an evaluation looks like.

Menopause isn't a disease, but the symptoms can be genuinely disruptive, and the decision about treating them deserves better than a headline from 2002 or a hallway rumor. The history here is messy because medicine is messy. What I hope you take from it is permission to ask better questions, and to expect an actual conversation rather than a blanket yes or no.

If you're in or around Southlake and you've been putting off asking, I'd rather you ask. That's what I'm here for.